Orphan Drugs and Rare Diseases UK 2017: Discussing strategies for patient engagement, market access, and gene therapies to enhance rare disease and orphan drug research.
Join us this October for strategic direction from the Rare Disease community and leverage your knowledge with the key requirements and tools for successful patient recruitment and retention through informed guidance delivered by a panel of industry experts including Actelion Pharmaceuticals, Birmingham Children’s Hospital, Vertex, Alexion Pharma GmbH, GlaxoSmithKline, and Sanofi.
Aimed at an audience of senior scientists and rare disease specialists involved in targeting rare diseases therapies and drug research, Orphan Drugs UK 2017 will provide a perfect platform to discuss pioneering clinical developments and the next generation of clinical trial process. The 7th annual conference will capture expert insight through dedicated focus new therapies for different rare diseases, the importance of orphan drug development and reimbursement and repurposing.
Find more details here